Cited by 29Estrogen and related hormone effectsEndometrial and Cervical Cancer TreatmentsCancer, Lipids, and Metabolism

Blocking 17β-hydroxysteroid dehydrogenase type 1 in endometrial cancer: A potential novel endocrine therapeutic approach

Open access
Konings, Gonda FJ, Cornel, Karlijn MC, Xanthoulea, Sofia, Delvoux, Bert, Skowron, Margaretha A, Kooreman, Loes, Koskimies, Pasi, Krakstad, Camilla +9 more·2018·The Journal of Pathology

Abstract

The enzyme type 1 17β-hydroxysteroid dehydrogenase (17β-HSD-1), responsible for generating active 17β-estradiol (E2) from low-active estrone (E1), is overexpressed in endometrial cancer (EC), thus implicating an increased intra-tissue generation of E2 in this estrogen-dependent condition. In this study, we explored the possibility of inhibiting 17β-HSD-1 and impairing the generation of E2 from E1 in EC using in vitro, in vivo, and ex vivo models. We generated EC cell lines derived from the well-differentiated endometrial adenocarcinoma Ishikawa cell line and expressing levels of 17β-HSD-1 similar to human tissues. In these cells, HPLC analysis showed that 17β-HSD-1 activity could be blocked by a specific 17β-HSD-1 inhibitor. In vitro, E1 administration elicited colony formation similar to E2, and this was impaired by 17β-HSD-1 inhibition. In vivo, tumors grafted on the chicken chorioallantoic membrane (CAM) demonstrated that E1 upregulated the expression of the estrogen responsive cyclin A similar to E2, which was impaired by 17β-HSD-1 inhibition. Neither in vitro nor in vivo effects of E1 were observed using 17β-HSD-1-negative cells (negative control). Using a patient cohort of 52 primary ECs, we demonstrated the presence of 17β-HSD-1 enzyme activity (ex vivo in tumor tissues, as measured by HPLC), which was inhibited by over 90% in more than 45% of ECs using the 17β-HSD-1 inhibitor. Since drug treatment is generally indicated for metastatic/recurrent and not primary tumor, we next demonstrated the mRNA expression of the potential drug target, 17β-HSD-1, in metastatic lesions using a second cohort of 37 EC patients. In conclusion, 17β-HSD-1 inhibition efficiently blocks the generation of E2 from E1 using various EC models. Further preclinical investigations and 17β-HSD-1 inhibitor development to make candidate compounds suitable for the first human studies are awaited. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Integrity signals

Registry

Crossref · 10.1002/path.5004

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Konings, G. F., Cornel, K. M., Xanthoulea, S., Delvoux, B., Skowron, M. A., Kooreman, L., Koskimies, P., Krakstad, C., Salvesen, H. B., van Kuijk, K., Schrooders, Y. J., Vooijs, M., Groot, A. J., Bongers, M. Y., Kruitwagen, R. F., ENITEC, & Romano, A.
Affiliations
  • Maastricht University Medical Centre (NL)
  • Heinrich Heine University Düsseldorf (DE)
  • Forendo Pharma Ltd Turku Finland
  • Haukeland University Hospital (NO)
  • GROW – School for Oncology and Developmental Biology Maastricht University The Netherlands
  • Maastricht University (NL)
Corresponding author
Romano, Andrea
Venue
The Journal of Pathology
Publisher
Wiley
Published
2018-01-03
Volume
244
Issue
2
Pages
203-214
ISSN
  • 0022-3417 (ISSN-L)
  • 1096-9896
OpenAlex
W2769122162
Cited by
26
References
48
Citations by year
2026: 2 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 1 · 2018: 9
FWCI
1.82
Type
journal article
Language
en
Open access
Locations
  • The Journal of Pathology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (acceptedVersion, other-oa)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
Funders
KWF Kankerbestrijding (UM-13-5782)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
endometrial cancer, estrone, estradiol, enzyme inhibition, endocrine therapy, estrogen metabolism, Ishikawa cells, chicken chorioallantoic membrane, cyclin A, metastasis
MeSH terms
Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Chick Embryo, Enzyme Inhibitors, Estradiol, Estradiol Dehydrogenases, Estrone, Female, Humans, Middle Aged, Signal Transduction, Endometrial Neoplasms, Cyclin A, Cell Line, Tumor, Cell Proliferation, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review